Biomedicines
February 25, 2026
Alice Melani, Giorgia Papini, Marco Bonaso et al.
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics as breakthrough therapies for mental disorders. Psychedelics can influence cognitive and emotional processes, showing solid therapeutic potential, particularly in treatment-resistant psychiatric disorders. Amongst the most promising compounds,...
Apollo (University of Cambridge)
February 24, 2026
Christian A. Webb, Boyu Ren, Verena Hinze et al.
Importance: Depression most commonly first emerges during adolescence, making early prevention critical. While school-based mindfulness training (SBMT) offers a scalable prevention approach with broad reach, evidence of its effectiveness is mixed, and there is a compelling case for a more personalized approach to prevention. Objective: To develop a data-driven algorithm from baseline...
International Journal of Innovative Science and Research Technology
February 24, 2026
T. Mallick
The current review focused to gather the available reports whether Rajyoga meditation have an effective role for overcoming post-traumatic stress disorder (PTSD) and allied reactions in a flood situation. The purpose of this article is to analyses the flood victims’ conditions, their psychosomatic illness in Indian context followed by comparing the scenario with slum people of Arambagh Block,...
Vidhyayana
February 23, 2026
B Santhanam
Our thoughts are the foundations for wellbeing and happiness. One must practice regulating his/her thoughts to manage Stress. Stress may be conceptualized as a form of mental fatigue, characterized by difficulties in forward thinking, an inability to maintain focus, reduced clarity, and a diminished motivation to engage with tasks. Within this framework, ignorance is understood as a lack of...
Indian Journal of Psychiatry
February 23, 2026
Rajdeep Birdi, Umesh Achary, Anirudh Bakam
Dear editor, We read with great interest the article titled “Ketamine’s double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant obsessive compulsive disorder (OCD)—A case series” by Kumar et al.,[1] which we discussed in detail during our departmental journal club. The article addresses a highly relevant and complex area in psychiatry, exploring novel...
Behavioral Sciences
February 23, 2026
Joshua Lipson, Hannes Kettner, Robin Carhart-Harris et al.
BACKGROUND: The quality and valence of psychedelic experiences are influenced by a range of psychological and contextual factors. This study examines baseline mood and the "relational triad"-comprising social connectedness, mindfulness, and spirituality-as potential predictors of the quality of naturalistic psychedelic experiences. METHODS: Data were drawn from the Predicting Responses to...
Acta neurológica colombiana
February 23, 2026
Ashly Verónica Arias, Mariana Carrillo Ramírez, Alejandro Hurtado López et al.
Introducción: la depresión es un trastorno psiquiátrico prevalente que impacta significativamente la calidad de vida de los individuos afectados. A pesar de los avances en los tratamientos farmacológicos, existen limitaciones tanto en su eficacia como en la duración de sus efectos terapéuticos. En este contexto, la psilocibina ha emergido como una herramienta prometedora en intervenciones...
BMJ
February 23, 2026
Edward Jacobs, Zarmeen Zahid, Jared T. Hinkle et al.
5 citations
Over the past 15 years, psychedelic treatments have garnered substantial clinical interest, with psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) advancing to phase 3 trials for various psychiatric conditions. This state-of-the-art review examines the evidence for these treatments and their proposed mechanisms of action, and identifies key challenges in clinical translation. Psychedelic...
Biomedicines
February 21, 2026
Maximiliano Ganado, Carmen Rubio, Javier Pérez-villavicencio et al.
The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this paradigm incompletely explains the diversity of neurobiological and therapeutic effects observed across psychedelic compounds. Non-classical psychedelics such as salvinorin A, the primary active constituent of Salvia divinorum, challenge this...
Current Addiction Reports
February 21, 2026
Draulio B Araujo, Lucas O. Maia, Tiago Arruda Sanchez et al.
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in treating depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical work shows enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging reveals decreased default...